Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Identification, genetic testing, and management of hereditary melanoma.

Leachman SA, Lucero OM, Sampson JE, Cassidy P, Bruno W, Queirolo P, Ghiorzo P.

Cancer Metastasis Rev. 2017 Mar;36(1):77-90. doi: 10.1007/s10555-017-9661-5.

2.

Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.

Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, Papargiris M, Lawrence MG, Timms L, Murphy DG, Frydenberg M, Hopkins JF, Bolton D, Clouston D, McPherson JD, van der Kwast T, Boutros PC, Risbridger GP, Bristow RG.

Nat Commun. 2017 Jan 9;8:13671. doi: 10.1038/ncomms13671.

3.

A Novel Pathogenic BRCA1 Splicing Variant Produces Partial Intron Retention in the Mature Messenger RNA.

Esposito MV, Nunziato M, Starnone F, Telese A, Calabrese A, D'Aiuto G, Pucci P, D'Aiuto M, Baralle F, D'Argenio V, Salvatore F.

Int J Mol Sci. 2016 Dec 21;17(12). pii: E2145. doi: 10.3390/ijms17122145.

4.

Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.

Na R, Zheng SL, Han M, Yu H, Jiang D, Shah S, Ewing CM, Zhang L, Novakovic K, Petkewicz J, Gulukota K, Helseth DL Jr, Quinn M, Humphries E, Wiley KE, Isaacs SD, Wu Y, Liu X, Zhang N, Wang CH, Khandekar J, Hulick PJ, Shevrin DH, Cooney KA, Shen Z, Partin AW, Carter HB, Carducci MA, Eisenberger MA, Denmeade SR, McGuire M, Walsh PC, Helfand BT, Brendler CB, Ding Q, Xu J, Isaacs WB.

Eur Urol. 2017 May;71(5):740-747. doi: 10.1016/j.eururo.2016.11.033. Epub 2016 Dec 15.

PMID:
27989354
5.

Germline BAP1 alterations in familial uveal melanoma.

Rai K, Pilarski R, Boru G, Rehman M, Saqr AH, Massengill JB, Singh A, Marino MJ, Davidorf FH, Cebulla CM, H Abdel-Rahman M.

Genes Chromosomes Cancer. 2017 Feb;56(2):168-174. doi: 10.1002/gcc.22424. Epub 2016 Oct 26.

PMID:
27718540
6.

Translational and clinical implications of the genetic landscape of prostate cancer.

Spratt DE, Zumsteg ZS, Feng FY, Tomlins SA.

Nat Rev Clin Oncol. 2016 Oct;13(10):597-610. doi: 10.1038/nrclinonc.2016.76. Epub 2016 Jun 1. Review.

7.

Genetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing.

Stanislaw C, Xue Y, Wilcox WR.

Cancer Biol Med. 2016 Mar;13(1):55-67. doi: 10.28092/j.issn.2095-3941.2016.0002.

8.

Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer.

Hart SN, Ellingson MS, Schahl K, Vedell PT, Carlson RE, Sinnwell JP, Barman P, Sicotte H, Eckel-Passow JE, Wang L, Kalari KR, Qin R, Kruisselbrink TM, Jimenez RE, Bryce AH, Tan W, Weinshilboum R, Wang L, Kohli M.

BMJ Open. 2016 Apr 15;6(4):e010332. doi: 10.1136/bmjopen-2015-010332.

9.

Association of polymorphisms with a family history of cancer and the presence of germline mutations in the BRCA1/BRCA2 genes.

Fernandes GC, Michelli RA, Scapulatempo-Neto C, Palmero EI.

Hered Cancer Clin Pract. 2016 Jan 13;14:2. doi: 10.1186/s13053-015-0042-1. eCollection 2016.

10.

The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safety.

Sermijn E, Delesie L, Deschepper E, Pauwels I, Bonduelle M, Teugels E, De Grève J.

Fam Cancer. 2016 Apr;15(2):155-62. doi: 10.1007/s10689-015-9854-4.

11.

Double Heterozygosity of BRCA2 and STK11 in Familial Breast Cancer Detected by Exome Sequencing.

Ataei-Kachouei M, Nadaf J, Akbari MT, Atri M, Majewski J, Riazalhosseini Y, Garshasbi M.

Iran J Public Health. 2015 Oct;44(10):1348-52.

12.

BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder.

Rocca CJ, Soares DG, Bouzid H, Henriques JA, Larsen AK, Escargueil AE.

Cell Cycle. 2015;14(13):2080-90. doi: 10.1080/15384101.2015.1042632.

13.

Interest in genomic SNP testing for prostate cancer risk: a pilot survey.

Hall MJ, Ruth KJ, Chen DY, Gross LM, Giri VN.

Hered Cancer Clin Pract. 2015 Apr 8;13(1):11. doi: 10.1186/s13053-015-0032-3. eCollection 2015.

14.

The construction of common and specific significance subnetworks of Alzheimer's disease from multiple brain regions.

Kong W, Mou X, Zhang N, Zeng W, Li S, Yang Y.

Biomed Res Int. 2015;2015:394260. doi: 10.1155/2015/394260. Epub 2015 Mar 19.

15.

Identification of a new BRCA2 large genomic deletion associated with high risk male breast cancer.

Timoteo AR, Albuquerque BM, Moura PC, Ramos CC, Agnez-Lima LF, Walsh T, King MC, Lajus TB.

Hered Cancer Clin Pract. 2015 Jan 16;13(1):2. doi: 10.1186/s13053-014-0022-x. eCollection 2015.

16.

Genetics of breast cancer: a topic in evolution.

Shiovitz S, Korde LA.

Ann Oncol. 2015 Jul;26(7):1291-9. doi: 10.1093/annonc/mdv022. Epub 2015 Jan 20. Review.

17.

Prostate cancer screening characteristics in men with BRCA1/2 mutations attending a high-risk prevention clinic.

Walker R, Louis A, Berlin A, Horsburgh S, Bristow RG, Trachtenberg J.

Can Urol Assoc J. 2014 Nov;8(11-12):E783-8. doi: 10.5489/cuaj.1970.

18.

KCTD11 tumor suppressor gene expression is reduced in prostate adenocarcinoma.

Zazzeroni F, Nicosia D, Tessitore A, Gallo R, Verzella D, Fischietti M, Vecchiotti D, Ventura L, Capece D, Gulino A, Alesse E.

Biomed Res Int. 2014;2014:380398. doi: 10.1155/2014/380398. Epub 2014 Jun 19.

19.

A Paternally Inherited BRCA1 Mutation Associated with an Unusual Aggressive Clinical Phenotype.

Fostira F, Tsoukalas N, Konstantopoulou I, Georgoulias V, Christophyllakis C, Yannoukakos D.

Case Rep Genet. 2014;2014:875029. doi: 10.1155/2014/875029. Epub 2014 Feb 10.

20.

Prevalence of the HOXB13 G84E mutation among unaffected men with a family history of prostate cancer.

Handorf E, Crumpler N, Gross L, Giri VN.

J Genet Couns. 2014 Jun;23(3):371-6. doi: 10.1007/s10897-013-9672-5. Epub 2013 Dec 7.

Supplemental Content

Support Center